BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220125
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T235350
CREATED:20211109T085834Z
LAST-MODIFIED:20211109T121023Z
UID:32029-1643068800-1643327999@www.pharmajournalist.com
SUMMARY:6th Microbiome Movement - Drug Development Summit Europe
DESCRIPTION:Decipher Mechanisms of Action\, Understand Clinical Data & Ignite Partnership Opportunities to Accelerate Your Microbiome Research \n \nWhilst emerging phase 3 data is set to ignite investment and uncover the reality of microbiome-based therapeutics\, there remain analytical challenges and translational bottlenecks that the community must come together to overcome\, to redefine biopharmaceutical treatment and diagnostic options. \nThe community is now closer than ever to obtaining an available\, approved and commercial microbiome-based therapeutic. This conference joins scientists\, clinicians\, entrepreneurs and academics\, to help assist this success. Persistent hurdles and ongoing challenges with microbiome drug development mean that real-life discussions and learnings are imperative to moving this exciting field forward. \nFrom understanding the microbiome functionality\, leveraging lessons from pre-clinical and clinical development\, scaling manufacturing processes and regulation hurdles\, our discussion will leave you with a holistic view of the European end-to-end development of microbiome therapeutics. \nThe Microbiome Movement provides the perfect opportunity to actualise the therapeutic promise that the microbiome has provided\, by bringing these challenges to the forefront and tackling them head on over three days of extensive content. With the sharing overall aim to commercialise a microbiome-based product. \nTo know more visit: https://ter.li/rk0suq
URL:https://www.pharmajournalist.com/event/6th-microbiome-movement-drug-development-summit-europe/
LOCATION:The Tower Hotel\, St. Katharine's Way\, London\, E1W 1LD\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220125
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T235350
CREATED:20211118T125316Z
LAST-MODIFIED:20211118T125437Z
UID:32119-1643068800-1643327999@www.pharmajournalist.com
SUMMARY:HFpEF Drug Discovery & Development Summit 2022
DESCRIPTION:Heart failure affects about 6.2 million people in the United States\, with half of the patients having heart failure with preserved ejection fraction (HFpEF) and counting. Yet\, there is no treatment for this form of the disease as HFpEF is a heterogeneous syndrome and\, like other disease areas\, this makes it difficult to develop effective therapeutics that will work for patients in each of the subtypes. \nThe HFpEF Drug Discovery & Development Summit 2022 is the first industry-specific forum exclusively focused on showcasing the latest drug development and translational research in HFpEF and its relationship with metabolic syndromes and co-morbidities\, whilst giving you the pivotal insights you need to kickstart the next generation of clinically defining therapeutics for HFpEF to avoid late-stage clinical trial failures. \nWith 20+ hours of content\, an interactive workshop\, and over 5 hours of networking with key industry leaders from Amgen\, Cardiobiopharma\, AstraZeneca\, NeoProgen\, Eli Lilly\, Bayer\, Novartis\, and more\, this comprehensive forum will completely focus on innovative research and state of the art science in HFpEF and the current challenges and opportunities in the field. \nMake this your 2022 must-attend meeting and network with 80+ senior CSOs\, CEOs\, research scientists\, and academics committed to tackling this form of heart failure and provide a meaningful impact on the lives of over 3.1 million patients suffering from HFpEF worldwide. \nTake a look at the full event guide here.
URL:https://www.pharmajournalist.com/event/hfpef-drug-discovery-development-summit-2022/
LOCATION:Omni Parker House\, 60 School St\, Boston\, MA\, 02108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220125
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T235350
CREATED:20211119T092845Z
LAST-MODIFIED:20211119T094834Z
UID:32188-1643068800-1643327999@www.pharmajournalist.com
SUMMARY:TGF-β for Immuno-Oncology Drug Development Summit
DESCRIPTION:It is clear the world of TGF-β contains vast potential and excitement\, in the past year alone we have seen great advances\, clinical setbacks\, and novel insights into the role of TGF-β. \nOver the last 12 months\, we have seen so many highs and lows\, including clinical updates from large pharma such as Novartis\, Oncotelic Therapeutics\, Sanofi. It is also exciting to see emerging biotechs progressing in this area – from Transcenta’s clearance with the FDA for Ph1 anti-PD-L1/TGFb antibody to Lassen Therapeutics uncloaking $31m for their candidate. \nWith the vast volume of candidates moving into the clinic\, it is vital for this community to reconnect at the 2nd TGF-β for Immuno-Oncology Drug Development Summit\, the definitive industry-led meeting to harness the therapeutic potential of this target and supercharge pipeline progression. \nTailored with 31+ senior leaders\, the 2022 meeting will return with a fresh speaker line-up and dedicated 2 tracks content for a comprehensive guide on TGF-β in immuno-oncology. Whether you are new to this field or a seasoned expert\, this meeting will provide you with the must-know takeaways from biology to translational modeling\, from biomarkers to clinical trial design across 3 days. \nWhat’s New? \n\n31+ world-class speakers from Scholar Rock\, Novartis\, Pfizer\, Mestag Therapeutics\, Takeda\, Cue Bio\, Genentech\, and more\n2 Dedicated Tracks of exclusive preclinical and clinical case studies and data for your invaluable lessons learned\nA TGF-β Boot Camp Day to provide a comprehensive guide on harnessing the potential of this complex target\n\nTo know more visit: https://ter.li/nep8yi
URL:https://www.pharmajournalist.com/event/tgf-%ce%b2-for-immuno-oncology-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220125
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T235350
CREATED:20211119T093246Z
LAST-MODIFIED:20211119T094530Z
UID:32193-1643068800-1643327999@www.pharmajournalist.com
SUMMARY:DDR\, ATR & PARP Inhibitors Summit
DESCRIPTION:The 5th Annual PARP\, ATR & DDR Inhibitors Summit is the one-of-a-kind industry-focused summit dedicated to bringing new and novel next-generation DDR therapeutics to the clinic and finding optimal treatment combinations to expand application in multiple cancer indications. \nThis is the key in-person biopharma conference for any research team developing inhibitors of specific DDR targets\, in either monotherapy or in combination\, to treat predictable\, identifiable\, DDR-defective cancer indications. \nIf you are a research team striving to create best-in-class DDR therapeutics\, this is the specific networking forum that has been curated with you in mind. \nWhat Will We Cover? \n\nDelve into the progress in PARP\, ATR & Wee1 including biomarker understanding with AstraZeneca\, Bayer\, Repare\, Merck KGaA\, Atrin Pharma\, IMPACT Therapeutics\, Onxeo\, FoRx & Zentalis\n\n\nOptimize pre-clinical development through models\, novel methodologies & imaging technologies to revolutionize translation with NCI\, XPose Therapeutics\, Dana-Farber Cancer Institute & Harvard\n\n\nUncover the therapeutic potential & progress in targeting Polθ\, WRN\, CHK1\, DNA-PK\, USP1\, PARG\, PKMYT1 with Artios Pharma\, Harvard\, NERx Bio\, KSQ Therapeutics\, IDEAYA & Repare Therapeutics\n\n\nDiscover the clinical updates on combination\, dosing\, scheduling & future directions for this exploding field with Newcastle University\, MD Anderson\, National Brain Tumor Society\, Yale\, Breakpoint Therapeutics & Harvard\n\n\nNetwork In Person with your peers\, ask your burning questions\, build connections\, and fully immerse yourself in the world of DDR therapeutics.\n\n\nA Virtual Attendance Option\, giving you access to the same premium quality content as the in-person event\, dedicated virtual networking opportunities\, & the ability to engage with our event partners\n\nTo know more visit: https://ter.li/uzjvgi
URL:https://www.pharmajournalist.com/event/ddr-atr-parp-inhibitors-summit/
LOCATION:Hyatt Regency Boston\, One Ave. de Lafayette\, Boston\, MA\, 02111\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220125
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T235350
CREATED:20211122T104255Z
LAST-MODIFIED:20220104T174404Z
UID:32208-1643068800-1643327999@www.pharmajournalist.com
SUMMARY:mRNA- Based Therapeutics Summit Europe
DESCRIPTION:Built with biopharmaceutical industry insights\, this conference will bring together key opinion leaders from Europe and the rest of the world to delve deep into the challenges associated with successfully designing and developing the next-generation of mRNA-based vaccines & therapeutics with improved specificity\, delivery & efficacy for immuno-oncology\, infectious diseases and beyond. \nWith 20+ pioneering large pharma\, biotech and academic experts who are shaping the landscape of mRNA- based therapeutics for the scientific community world-wide\, hear how they address the major challenges facing the industry. \nKey Highlights: \n\nOptimise the Efficacy\, Cell- & Tissue- Specificity & Translatability of Your mRNA- Based Pipeline\n\n With the limitless opportunity of mRNA- based Therapeutics across different modalities\, consider the challenges of efficacy and improve cell- & tissue- specificity with expert insights from Professor Drew Weissman\, Strand Therapeutics & Chalmers University of Technology  \n\nExplore Applications of mRNA- Based Therapeutics Beyond Infectious Diseases\n\n From immune-oncology to rare and autoimmune diseases\, dive into emerging applications and potential challenges of mRNA- based vaccines and therapeutics beyond infectious diseases with case studies from Moderna\, BioNTech & Ethris  \n\nNavigate New & Emerging Delivery Technologies for mRNA- Based Therapeutics\n\n Take yourself to the forefront of mRNA delivery system development\, from structure through to administration with insights from BioNTech\, Johnson & Johnson & 20Med Therapeutics  \n\nStrategise Your Scalable & Global mRNA-Based Vaccine Development \n\n With the global outreach of mRNA- based vaccines\, scalability is a major hurdle. Hear the latest technological advances and regulatory standards in mRNA- based vaccine and therapeutic landscape from Sanofi\, Ziphius Vaccines & Arcturus Therapeutics  \n\nTune into How Companies are Differentiating Their Pipelines Beyond mRNA- Based Vaccines\n\n With the success of mRNA- based vaccines fulfilling novel technologies and therapies such as mRNA- based protein replacement\, hear from companies like Strand Therapeutics\, Turn Biotechnologies & Orna Therapeutics on the emerging strategies that will enable innovation in the field \nTo know more visit: https://ter.li/og1teo
URL:https://www.pharmajournalist.com/event/mrna-based-therapeutics-summit-europe/
LOCATION:Digital Event – CET
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220126
DTEND;VALUE=DATE:20220128
DTSTAMP:20260515T235350
CREATED:20211118T130234Z
LAST-MODIFIED:20211118T130317Z
UID:32130-1643155200-1643327999@www.pharmajournalist.com
SUMMARY:5th Antigen-Specific Immune Tolerance Summit
DESCRIPTION:Returning for its fifth year\, the Antigen-Specific Immune Tolerance Summit will lean into the industry’s key challenges of understanding the mechanisms inducing tolerance\, characterizing driver antigens of disease\, monitoring immune response\, and accelerating durable therapies into the clinic. \nThis is your comprehensive guide to define your drug development strategy for 2022 and delve into the therapeutic opportunity held by the next generation of antigen-specific immunotherapies. Expect to be involved in interactive discussions on: \n\nExamining the mechanisms underlying immune tolerance to drive antigen and epitope discovery with insights from the NIH\, Vaccibody\, and Imcyse\nLeveraging immune biomarkers and explore immune tolerance in diabetes with Novo Nordisk\, COUR Pharmaceuticals\, and Diamyd Medical\nExploring the diversity of technologies and platforms for antigen delivery withToleranzia\, Idogen AB\, and AnTolRx\, Inc\nOptimizing clinical durability and efficacy of antigen-specific immunotherapies with insights from WORG Pharmaceuticals\, and Cellerys\n\nUniting 80+ industry experts to discuss cutting-edge content exploring the latest advances in the field of antigen-specific immune tolerance\, this is a conversation not to miss. \nTake a look at the event guide here.
URL:https://www.pharmajournalist.com/event/5th-antigen-specific-immune-tolerance-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR